By Iain Gilbert
Date: Tuesday 26 Aug 2025
(Sharecast News) - Analysts at RBC Capital Markets hiked their target price on gene and cell therapy firm OXB from 800p to 930p on Tuesday following its recent oversubscribed £60m equity funding and revenue guidance reiteration.
Update to stated post-offer intention statement | 27-Aug-2025 | 16:30 | RNS |
Oxford Instruments Plc - Holding(s) in Company | 27-Aug-2025 | 16:20 | PR Newswire |
Form 8.3 - Spectris plc - Amendment | 27-Aug-2025 | 15:42 | RNS |
Form 8.3 - Spectris Plc | 27-Aug-2025 | 15:32 | RNS |
Form 8.3 - SPT LN | 27-Aug-2025 | 15:30 | RNS |
Questor:Meggitt | 23-Dec-2014 | Telegraph |
Questor :KCOM | 27-Nov-2014 | Telegraph |
Questor :Ricardo | 31-Oct-2014 | Telegraph |
Questor:CSR | 17-Oct-2014 | Telegraph |
Questor:BAE Systems | 03-Sep-2014 | Telegraph |
Price | 5,411.54 |
Change Today | 8.71 |
% Change | 0.16 % |
27-Aug-25 Close | 5,411.54 |
You are here: research